Drug Trial Radar · NCT03101488
Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
287
Actual
Start
Mar 21, 2017
Primary completion
Sep 2, 2019
Study completion Aug 25, 2020
Sponsor
- Lead sponsor
- 3D Medicines (Sichuan) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 5, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This dose escalation and dose expansion study is to evaluate and characterize the tolerability and safety profile of single agent KN035 in Chinese adult subjects with unresectable advanced carcinoma.
Conditions
- Solid Tumors
Interventions
KN035Drug
KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities (DLTs) in dose escalation studyTime frame: From screening to up to cycle 1 (28 days)
- Percentage of participants with adverse events (AEs), serious adverse events and AEs of special interestTime frame: From screening to up to 1 months after the last dose of study drug (up to approximately 2 years)
- ORR of HCC patients in dose expansion studyTime frame: Up to 2 approximately years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Affiliated Hospital of Military academy of medical sciences
Beijing, China
Hunan Cancer Hospital
Changsha, Hunan, China
First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Zhongshan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.